Galectin Therapeutics (GALT) CMO exits 52,037 shares in pre-planned sale

Rhea-AI Filing Summary

GALECTIN THERAPEUTICS INC Chief Medical Officer Jamil Khurram exercised and sold stock options in a paired set of transactions. On June 26 and 29, 2026, he exercised options covering 52,037 shares of common stock at exercise prices of $2.20 and $2.50 per share, then sold the same number of shares in open‑market sales around $5.00–$5.04 per share. The filing shows these trades were executed under a Rule 10b5-1 trading plan adopted on February 2, 2026, and reports that Khurram held no remaining common shares or related options from these grants immediately after the transactions.

Insights

Equity analyst

CMO executes pre-planned option exercise-and-sell, exiting 52,037 shares.

Chief Medical Officer Jamil Khurram exercised stock options for 52,037 Galectin Therapeutics shares at exercise prices of $2.20 and $2.50, then sold the same number of shares in open‑market trades around $5.00–$5.04 per share.

The filing states these transactions were carried out under a Rule 10b5-1 plan adopted on February 2, 2026, indicating they were pre‑scheduled rather than opportunistic. Following the trades, Khurram shows zero common shares and no remaining options from these grants, so this represents a full exit from this particular equity position.

Because the activity is classified as routine option exercise-and-sale under a pre‑arranged plan, it is typically interpreted as neutral context on insider ownership rather than a new signal about GALT's operating performance. Future company filings may update whether he receives new equity awards or rebuilds a share position.

Insider Trade Summary 10b5-1

Net Seller: 52,037 shares ($262,084)

Net Sell 9 txns

Insider Jamil Khurram

Role Chief Medical Officer

Sold 52,037 shs ($262K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	47,467	$0.00	--
Exercise	Common Stock	47,467	$2.50	$119K
Sale	Common Stock	47,467	$5.04	$239K
Exercise	Stock option (right to buy)	2,037	$0.00	--
Exercise	Stock Option (right to buy)	2,533	$0.00	--
Exercise	Common Stock	2,037	$2.20	$4K
Sale	Common Stock	2,037	$5.00	$10K
Exercise	Common Stock	2,533	$2.50	$6K
Sale	Common Stock	2,533	$5.00	$13K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 47,467 shares (Direct, null); Stock option (right to buy) — 100,000 shares (Direct, null)

Footnotes (1)

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026 The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027. The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Key Figures

Shares sold: 52,037 shares Sale prices: $5.00–$5.13 per share Weighted average sale price: $5.04 per share +4 more

7 metrics

Shares sold 52,037 shares Open-market sales on June 26 and 29, 2026

Sale prices $5.00–$5.13 per share Price ranges from weighted-average sale footnotes

Weighted average sale price $5.04 per share June 29, 2026 common stock sale entry

Option exercise prices $2.20 and $2.50 per share Common stock entries marked as derivative exercises

Options exercised 52,037 options transactionSummary exerciseShares total

Rule 10b5-1 plan adoption February 2, 2026 Footnote describing trading plan for reported transactions

Post-transaction common holdings 0 shares total_shares_following_transaction fields for common stock

Key Terms

Rule 10b5-1 plan, Stock Option (right to buy, weighted average sale price, vested, +1 more

5 terms

Rule 10b5-1 plan regulatory

"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (right to buy financial

"Stock Option (right to buy) with an underlying security title of Common Stock"

weighted average sale price financial

"This amount represents the weighted average sale price of such transactions."

vested financial

"The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027."

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 07:23 PM Accepted by SEC EDGAR 06/30/2026 - 07:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jamil Khurram

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GEORGIA 30071

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		M(1)		2,037	A	$2.2	2,037	D
Common Stock	06/26/2026		S(1)		2,037	D	$5(2)	0	D
Common Stock	06/26/2026		M(1)		2,533	A	$2.5	2,533	D
Common Stock	06/26/2026		S(1)		2,533	D	$5(2)	0	D
Common Stock	06/29/2026		M(1)		47,467	A	$2.5	47,467	D
Common Stock	06/29/2026		S(1)		47,467	D	$5.04(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.2	06/26/2026		M(1)			2,037	03/11/2025(3)	03/20/2034	Common Stock	2,037	$0	100,000	D
Stock Option (right to buy)	$2.5	06/26/2026		M(1)			2,533	04/30/2025(4)	08/01/2034	Common Stock	2,533	$0	47,467	D
Stock Option (right to buy)	$2.5	06/29/2026		M(1)			47,467	07/31/2025(4)	08/01/2034	Common Stock	47,467	$0	0	D

Explanation of Responses:

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026

2. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. The options vested at a rate of one-third or 50,000 options on each of March 11, 2025, March 11, 2026 and March 11, 2027.

4. The options vested at a rate of twenty five percent or 25,000 options on each of October 31, 2024, January 31, 2025, April 30, 2025 and July 31, 2025.

5. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.13. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	Jack W. Callicutt, by power of attorney	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did GALT Chief Medical Officer Jamil Khurram report in this Form 4?

Jamil Khurram reported exercising options for 52,037 shares of Galectin Therapeutics common stock and selling the same 52,037 shares in open-market transactions around $5.00–$5.04 per share. After these trades, the filing shows no remaining common stock from these grants.

How many GALECTIN THERAPEUTICS INC (GALT) shares did the CMO sell and at what prices?

The CMO sold 52,037 GALT common shares in multiple open-market trades on June 26 and 29, 2026. Weighted average sale prices were about $5.00 and $5.04 per share, with individual trades ranging from $5.00 to $5.13 according to the Form 4 footnotes.

Were the GALT insider stock sales made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the reported transactions were made under a Rule 10b5-1 trading plan adopted on February 2, 2026. Such plans pre-schedule trades, indicating the timing of these June 2026 sales was arranged in advance rather than decided opportunistically.

What stock options did the GALT CMO exercise before selling shares?

Khurram exercised stock options covering 52,037 shares of Galectin Therapeutics common stock. The options carried exercise prices of $2.20 and $2.50 per share, with vesting schedules described in the footnotes, before all the resulting shares were sold in the open market soon afterward.

Does the GALT Form 4 show any remaining holdings for the CMO after these trades?

The Form 4 reports total shares following the transactions as zero for the common stock entries and shows no remaining derivative positions in the derivative summary. This indicates Khurram no longer held common shares from these exercised options immediately after the reported trades.

What vesting schedule applied to the GALT stock options exercised in this filing?

Footnotes explain that one set of options vested in three equal tranches of 50,000 options on March 11, 2025, 2026, and 2027. Another set vested in four tranches of 25,000 options on October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025.